An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10
about
Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legsPolyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individualsStructural insights on the role of antibodies in HIV-1 vaccine and therapyAntigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cellsA Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing AntibodiesCrystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design ImplicationsCrystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 InteractionDistinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodiesStructure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing EpitopeA gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen RecognitionDisruption of Helix-Capping Residues 671 and 674 Reveals a Role in HIV-1 Entry for a Specialized Hinge Segment of the Membrane Proximal External Region of gp41Structural Basis for HIV-1 Neutralization by 2F5-Like Antibodies m66 and m66.6Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1)Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry.Generation of Long-Lived Bone Marrow Plasma Cells Secreting Antibodies Specific for the HIV-1 gp41 Membrane-Proximal External Region in the Absence of Polyreactivity.Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region.4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphismsAromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions.In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitutionCharacteristics of the earliest cross-neutralizing antibody response to HIV-1.Anti-idiotypic monobodies derived from a fibronectin scaffold.Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjectsAntibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralizationThe presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8.Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting.A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.Phages and HIV-1: from display to interplay.Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodiesA fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.Increased functional stability and homogeneity of viral envelope spikes through directed evolution.The immune response during acute HIV-1 infection: clues for vaccine development.In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadthStructure-based vaccine design in HIV: blind men and the elephant?
P2860
Q21090520-AACFBB3E-A956-458D-AA5C-5715A5B95DD1Q24635002-EBCF49F3-32B4-4038-8FEC-B6B6C16E0872Q26829461-5B8169CA-E737-437B-ACC2-0BACCA4D5EC2Q27320687-D905E052-6334-4C93-8C2B-25F85D0BE6F5Q27655865-B9C3007D-1C68-4601-99C7-6BB7FB432A13Q27657377-CEDB02BB-D731-465C-BAF2-9C9039684796Q27661588-31B1C798-09ED-4FF5-9D54-355500B91C85Q27665884-1170D8AD-AD7B-4421-8F4F-0B71EC688C07Q27675260-C4F23F03-9AAB-4061-B591-FD21A61D0A6FQ27676864-F1FE32FC-708C-4D2D-AD49-7DD33AEA49B4Q27680089-C82E111C-7324-4BED-B3BF-79FC881E85C4Q27680872-9F87988D-B80D-4F5E-A398-ECAAFC5C82F6Q28743199-E390E846-6970-4540-AC7E-9B7C4BB838B0Q30353709-2561A548-E7A5-412D-8074-8EA99D117E59Q30391094-EBD82900-53D7-4560-B92B-5576F6AE9333Q30843874-452BDC69-6AAA-4A67-B120-AB8806E7164FQ31132248-8435CD82-7331-42B2-9E85-C4D1E15821B6Q33508799-8C03A1BA-924F-479C-AE0E-7BC7E540075BQ33547451-E8DB1350-CE06-41D5-8ABD-9A199264EC9CQ33667654-778322E8-6394-466D-BC00-FD29CDF401F9Q33725718-FD6FAD02-A355-4191-8E25-EE9C66550DC2Q33778466-84D4326A-E983-454D-8A8D-E763E4896130Q33798076-D1D1DD49-D808-4C69-9C41-008C252057A0Q33876210-DB9B4A35-421C-440A-8778-3674742C87C9Q33888559-9B6AE803-E66E-486C-8A73-D4CF9DEFC866Q33946158-F852C487-F3CC-4B65-90BC-8BCF52A3CA55Q34017550-EE534BD5-2A29-47CF-ADF5-7A212369D7C2Q34042758-1A90C3C4-AC89-4BEB-9F7E-67056B7BD10FQ34047445-72B3B31B-435D-44CA-86B8-BDCF41FBED84Q34273397-C5A14C97-D92E-4767-900E-09E266EF8CEEQ34299053-B1DB721C-3BAA-4538-BB36-FFA692391D56Q34324992-5FDE5E76-1F60-40F0-82F9-A3E054566A3FQ34396912-F2148F30-7A1A-416B-B588-C3F08408DD31Q34517381-89B0F117-3085-43D9-828E-5C4C40BF58F9Q34594701-70620066-BFBF-46F0-8164-E9808B166D1EQ34594905-68C9DC71-ED0A-496E-9FB6-6CE385E3CDD2Q34611144-10F0FED0-489C-4657-A847-F64040A0E0A1Q34614862-207781C0-61A9-44AD-8EC2-55FBA2C3FF93Q34937404-85A90199-9D31-4DAA-9841-DBF34A592545Q34987048-53BA7A3A-DBF9-41C7-A561-46615E6A111E
P2860
An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
An affinity-enhanced neutraliz ...... between those of 2F5 and 4E10
@ast
An affinity-enhanced neutraliz ...... between those of 2F5 and 4E10
@en
An affinity-enhanced neutraliz ...... between those of 2F5 and 4E10.
@nl
type
label
An affinity-enhanced neutraliz ...... between those of 2F5 and 4E10
@ast
An affinity-enhanced neutraliz ...... between those of 2F5 and 4E10
@en
An affinity-enhanced neutraliz ...... between those of 2F5 and 4E10.
@nl
prefLabel
An affinity-enhanced neutraliz ...... between those of 2F5 and 4E10
@ast
An affinity-enhanced neutraliz ...... between those of 2F5 and 4E10
@en
An affinity-enhanced neutraliz ...... between those of 2F5 and 4E10.
@nl
P2093
P2860
P356
P1433
P1476
An affinity-enhanced neutraliz ...... between those of 2F5 and 4E10
@en
P2093
Ann Hessell
Dennis R Burton
Emma T Crooks
Florence M Brunel
James M Binley
Josh D Nelson
Michael B Zwick
Philip E Dawson
Richard Jensen
P2860
P304
P356
10.1128/JVI.02588-06
P577
2007-02-07T00:00:00Z